Welcome to our dedicated page for Koninklijke Phil news (Ticker: PHG), a resource for investors and traders seeking the latest updates and insights on Koninklijke Phil stock.
Royal Philips (Koninklijke Philips N.V., NYSE: PHG) is a health technology company whose news flow centers on diagnostic imaging, ultrasound, image-guided therapy, monitoring, enterprise informatics and personal health. Company announcements frequently highlight AI-enabled systems, new product launches and strategic portfolio moves, giving investors and observers insight into how Philips develops and positions its health technology offerings.
Recent Philips news has featured AI-powered innovations in image-guided therapy and diagnostic imaging, such as LumiGuide 3D Device Guidance for light-based navigation during minimally invasive procedures, DeviceGuide for AI-assisted tracking of heart valve repair devices, and Verida, a detector-based spectral CT system with AI integrated across the imaging chain. The company also reports advances in MRI through its BlueSeal Horizon 3.0T platform and extended partnerships in neuroimaging, such as the integration of Cortechs.ai quantitative analytics into Philips MR workflows.
News items also cover enterprise informatics and cloud-based solutions, including the launch of Philips Management 15, a web-based diagnostic viewer that delivers full radiology capabilities through a browser and interfaces with AI tools and interactive reporting. In addition, Philips communicates on long-term partnerships with health systems, monitoring agreements and large-scale deployments of its Azurion image-guided therapy systems.
Corporate and portfolio developments appear regularly in the news stream. Examples include the agreement to acquire SpectraWAVE Inc. to expand intravascular imaging and physiology solutions, and the completed carve-out of the Philips Emergency Care business, which now operates as Heartstream under a Philips brand license. Earnings-related releases and Form 6-K summaries provide context on comparable order intake, sales trends, margins, productivity programs and outlook.
Investors and healthcare professionals following PHG news can use this page to track product introductions, AI and imaging milestones, strategic transactions and quarterly performance updates that shape Philips’ role in global health technology.
Royal Philips (NYSE: PHG) has convened its Annual General Meeting of Shareholders (AGM) for 2023, scheduled for May 9, 2023, in Amsterdam. The agenda includes proposals to re-appoint Abhijit Bhattacharya as a Board of Management member and David Pyott and Liz Doherty as Supervisory Board members. Additionally, EY is proposed for re-appointment as external auditor for one year, and PricewaterhouseCoopers for a four-year term starting in 2025. Other recurring items include the 2022 Remuneration Report and proposals on financial statements and dividends.
Royal Philips (NYSE: PHG) has entered into a strategic partnership with the Champalimaud Foundation to significantly reduce the carbon footprint of its diagnostic and interventional imaging equipment by 2028. This collaboration aims to implement innovative solutions such as equipment upgrades, digitalization, and renewable energy sourcing. Global healthcare systems contribute 4.4% of CO₂ emissions, and this initiative is expected to enhance care quality while promoting sustainability. Philips will assist Champalimaud in modernizing its imaging technology, leveraging eco-friendly innovations like the Spectral CT 7500 and Ingenia Ambition 1.5T, which use significantly less energy and resources.
On March 7, 2023, Royal Philips (NYSE: PHG) announced a long-term strategic partnership with the Gibraltar Health Authority to enhance local cardiac care by establishing a new interventional cardiac suite at St Bernard’s Hospital. This initiative will eliminate the need for patients to travel to Spain for treatments like coronary angioplasty and catheterization. The suite's construction will take 9-12 months, improving patient outcomes and operational efficiency. Additionally, Philips will upgrade existing hospital equipment, including X-ray and ultrasound systems, supporting better diagnostic capabilities and expanding cardiology services.
Royal Philips (NYSE: PHG) announced the appointment of Julia Strandberg as Chief Business Leader of its Connected Care businesses, effective April 24, 2023. Ms. Strandberg, who previously served as Chief Commercial Officer at Pear Therapeutics, will join Philips’ Executive Committee and report to CEO Roy Jakobs. The Connected Care segment includes Monitoring, Sleep & Respiratory Care, and Enterprise Informatics. Strandberg’s appointment follows interim leadership by Dan Leonard since October 2022. The company is enhancing its leadership team with experienced professionals to drive growth and innovation in healthcare.
On March 6, 2023, Royal Philips (NYSE: PHG) presented key findings from clinical studies at the ACC.23/WCC event. A study revealed a 62% increase in intravascular imaging (IVI) use during percutaneous coronary interventions (PCI) from 2013 to 2019, correlating with lower mortality rates and improved cardiac outcomes. Another extensive analysis indicated that timely removal of infected cardiac implantable electronic devices (CIEDs) significantly lowers healthcare costs and hospitalization rates. Additionally, new data confirmed the safety and effectiveness of the Philips 3D Intracardiac Echocardiography Catheter – VeriSight Pro – in various cardiac procedures, enhancing patient care.
On March 2, 2023, Philips showcased its latest innovations in cardiology at the ACC.23/WCC event in New Orleans. The highlight is the Philips Ultrasound Compact System 5500 CV, enhancing bedside cardiac imaging. Clinical evidence presented by partners supports the efficacy of Philips cardiology solutions in improving patient care. Studies include over a million Medicare patients, evaluating intravascular imaging outcomes, and the safety of the Philips Intracardiac Echocardiography Catheter. Philips’ portfolio aims to meet the rising demand for effective management of heart conditions, backed by over 110 ongoing clinical studies.
On March 1, 2023, Royal Philips (NYSE: PHG) unveiled its innovative radiology portfolio at the European Congress of Radiology in Vienna. The showcased smart imaging systems and vendor-neutral workflow solutions aim to enhance clinical confidence and operational efficiency across radiology, oncology, cardiology, and pathology.
Philips highlighted its AI-powered SmartSpeed technology that can reduce MRI scan times by up to 64%, which is critical in addressing workforce shortages and improving patient outcomes. The company emphasizes its commitment to sustainability and delivering ongoing value to healthcare providers.
Summary not available.
Royal Philips (NYSE: PHG) released its Annual Report 2022, highlighting a challenging year marked by disappointing stakeholder results. The report will be discussed in the Annual General Meeting of Shareholders (AGM) scheduled for May 9, 2023. The company plans to enhance patient safety and quality, and improve operational execution in 2023. In response to shareholder feedback, the 2022 Remuneration Report indicates that no Annual Incentive or Long-term Incentive payouts will be made to Board members due to 2022’s performance. The Annual Report is filed with the Netherlands Authority and will also be filed with the US SEC.
Summary not available.